Company intelligence / Profile preview

Gritgen Therapeutics Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

GS1191, their lead product for Hemophilia A, has demonstrated excellent safety and sustained bleed control efficacy in clinical trials. Early data showed it can consistently increase FVIII activity in the blood, resulting in fewer bleeding episodes. Patients given the higher dose reached normal FVIII activity levels and had no bleeding episodes after dosing. Most side effects were mild with no serious side effects reported.

Therapeutic areas: ImmunologyMetabolic DisordersRare DiseasesHematology
Modalities: Gene therapyAAV-based gene therapy
Industry: Biotech

Drug pipeline

2 assets

GS001

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Gritgen Therapeutics Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gritgen Therapeutics Co., Ltd..

Explore the full profile